Initial research will be focusing on patients with multidrug-resistant, chronic infections associated with cystic fibrosis, organ transplantation, and implantable hardware (e.g. pacemakers joint replacements, etc.).
The first planned clinical trial will look at otherwise healthy cystic fibrosis patients that are shedding Pseudomonas aeruginosa, and will most likely start with one site located in San Diego, but may expand following successful initiation of the study. The start date for this study has yet to be determined.